Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE plus rituximab versus rituximab alone in relapsed or refractory follicular B-cell non-Hodgkin's lymphoma
2005-005777-30Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing VELCADE + MabThera with MabThera alone (2 arms). Primary endpoint: Progression-free survival. Started Jan 2006; status: completed.
02
Drugs
bortezomibrituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2005-005777-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005777-30.